Retatrutide

Last updated
Retatrutide
Retatrutide.svg
Clinical data
Other namesLY-3437943
Identifiers
  • L-tyrosyl-2-methylalanyl-L-glutaminylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-alpha -aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-2-methyl-L-leucyl-Lleucyl-L-alpha -aspartyl-L-lysyl-N6-(N-(19-carboxy-1-oxononadecyl)-L-gamma-glutamyl-2-(2-(2-aminoethoxy)ethoxy)acetyl)-L-lysyl-L-alanyl-L-glutaminyl-2-methylalanyl-L-alanyl-Lphenylalanyl-L-isoleucyl-L-alpha -glutamyl-L-tyrosyl-L-leucyl-L-leucyl-L-alpha -glutamylglycylglycyl-L-prolyl-L-seryl-L-serylglycyl-L-alanyl-L-prolyl-L-prolyl-L-prolyl-L-serinamide
CAS Number
UNII
ChEMBL

Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors). [1] It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial. [2] [3] [4]

Chemistry

The drug is a peptide with amino acid sequence [5] 

YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³

where superscript numbers refer to unique chemical modifications:

  1. "A¹" refers to 2-aminoisobutyric acid (AiB) instead of alanine.
  2. "L²" refers to alpha-methyl added to leucine (MeL, 2-methylleucine).
  3. "S³" refers to addition of an amino group to the C-terminal serine.
  4. "K⁴" refers to a modification group attached to the lysine's tail amine, specifically (AEEA)-gamma-Glu-C20 diacid.

References

  1. ↑ Coskun T, Urva S, Roell WC, et al. (September 2022). "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept". Cell Metabolism . 34 (9): 1234–1247.e9. doi: 10.1016/j.cmet.2022.07.013 . PMID   35985340. S2CID   251675508.
  2. ↑ "Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight". investor.lilly.com (Press release). Eli Lilly. 26 June 2023. Retrieved 3 July 2023.
  3. ↑ Constantino, Annika Kim (26 June 2023). "Eli Lilly experimental obesity drug could beat rivals in total weight loss for patients". CNBC.com. Retrieved 3 July 2023.
  4. ↑ Jastreboff AM, Kaplan LM, Frías JP, et al. (June 2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial". The New England Journal of Medicine . 389 (6): 514–526. doi:10.1056/NEJMoa2301972. PMID   37366315. S2CID   259260926. Free access subject to registration.
  5. ↑ "Compound Report Card". ebi.ac.uk. European Bioinformatics Institute, European Molecular Biology Laboratory. n.d. Retrieved August 5, 2024.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.